Latest Articles

Publication Date
All News Scientific
Essex teen says endometriosis shouldn't be 'taboo' as she shares her story - Clacton and Frinton Gazette

Essex teen says endometriosis shouldn't be 'taboo' as she shares her story Clacton and Frinton Gazette

Published: Dec. 4, 2024, 9:01 a.m.
Read Full Article
What is Visanne, the endometriosis drug just added to the PBS? - New Zealand Doctor Online

What is Visanne, the endometriosis drug just added to the PBS? New Zealand Doctor Online

Published: Dec. 4, 2024, 1:33 a.m.
Read Full Article
Woman's Doctor: Know the symptoms of endometrial cancer - MSN

Woman's Doctor: Know the symptoms of endometrial cancer MSN

Published: Dec. 3, 2024, 8:37 p.m.
Read Full Article
Elagolix with add-back therapy found effective and tolerable for endometriosis pain - Contemporary Obgyn

Elagolix with add-back therapy found effective and tolerable for endometriosis pain Contemporary Obgyn

Published: Dec. 3, 2024, 6:36 p.m.
Read Full Article
Condition affecting millions linked with premature death and cancer risks - Express

Condition affecting millions linked with premature death and cancer risks Express

Published: Dec. 3, 2024, 12:58 p.m.
Read Full Article
Woman Shocked To Wake Up From Routine Surgery To Find Doctors Removed An Extra Organ - Wide Open Country

Woman Shocked To Wake Up From Routine Surgery To Find Doctors Removed An Extra Organ Wide Open Country

Published: Dec. 3, 2024, 11:04 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer GlobeNewswire

Published: Dec. 3, 2024, 10:01 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Canada Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Canada Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance UK

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance UK

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!